Key result
Targeting the mitochondrial Kv1.3 channel in autoreactive T cells with PAPTP selectively induces apoptosis and reduces multiple sclerosis-like pathology in experimental models.
Why the study?
Does targeting the mitochondrial Kv1.3 channel in autoreactive T cells mitigate MS-like pathology?
Does targeting the mitochondrial Kv1.3 channel in autoreactive T cells mitigate MS-like pathology?
Targeting the mitochondrial Kv1.3 channel may provide a more specific therapeutic strategy for multiple sclerosis without broad immunosuppression.
Multiple sclerosis (MS), a chronic autoimmune disorder, is characterized by the infiltration of autoreactive T cells into the central nervous system (CNS), leading to myelin destruction and neurological deficits. Current therapies often lack specificity, resulting in broad immunosuppression and potential side effects. In this issue of EMBO Molecular Medicine, Angi, Varanita and colleagues (Angi et al, 2025) identify a novel therapeutic strategy in targeting the mitochondrial Kv1.3 channel in autoreactive T cells, offering a more selective approach to mitigate MS-like pathology. Pluchino and Willis discuss a study by Szabo et al (in this issue of EMBO Mol Med) that reveals a novel therapy to treat multiple sclerosis by targeting the mitochondrial Kv1.3 channel in autoreactive T cells.
No takes yet. Share an insight, caveat, or question.
Pluchino et al. (2025) conducted an editorial in Multiple sclerosis. PAPTP was evaluated. Targeting the mitochondrial Kv1.3 channel in autoreactive T cells with PAPTP selectively induces apoptosis and reduces multiple sclerosis-like pathology in experimental models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: